Navigation
banner
Together we Drive the Future

Antibody Drug Conjugates

2017-02-212017-02-212017-02-21
EARLY BIRD DISCOUNT! Register by Feb 21, 2017 to receive 20% off your registration!
Or register 3 for the price of 2 with the coupon code rcdvb!


registration button

Antibody & Protein Therapeutics Summit


Antibodies in Oncology & Infectious Diseases

Antibody Drug Conjugates

Novel Protein Therapeutics
 
 

Dear Colleague,

We invite you to attend the 3rd Antibody Drug Conjugates Conference, which will take place July 11-12, 2017 in Baltimore, MD. This event will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain a fresh perspective on the emergence of recent data from ADC clinical trials, new linkers and payloads, personalized healthcare, site specific attachment, and ADC therapeutics.

With the field of antibody drug conjugates rapidly expanding and the increasing number of ADC clinical trials, novel therapeutics are emerging. The ADC therapeutic area combines synthetic chemistry with rationale biology and is advancing monoclonal antibody treatments into the realm of precision medicine with improved effectiveness and therapeutic indices.

Session Topics:

  1. Clinical Developments: Human Phase Studies of Near-to-Market ADCs
  2. Novel ADCs: Preclinical & Translational Studies
  3. Novel Payloads & Linkers
  4. Alternative ADC Makeups/Strategies
  5. Targeted Combinations for Enhancing ADC Efficacy
  6. Analytical Methods for Streamlining ADC Manufacturing

We hope to see you there! 

 

Best regards,

The 2017 Advisory Committee

 

2017 Program Director
Victor-Jeffrey Leyton, Université de Sherbrooke
2017 Advisory Board Members
Neeraj Agrawal, Amgen
Ahuva Nissim, Queen Mary University
Amandeep Gakhal, Sutro Biopharma
Ann White, University of Southampton
Bill Harriman , Crystal Bioscience
Birgit Schoeberl, Merrimack Pharmaceuticals
Elad Firnberg, Revolve Biotechnologies
Ernesto Freire, Johns Hopkins University
Nicolas Fischer, Novimmune SA
Gregory Adams, Eleven Biotherapeutics
Janos Luka, Walter Reed Army Institute of Research
Matthew Robinson, Immunome, Inc
Michael R. Dyson, IONTAS Ltd
Andreas Pahl, Heidelberg Pharma
Pedro Berraondo López, CIMA, University of Navarra
Darren Schofield, MedImmune
Seema Kumar, EMD Serono
Jamshid Tanha, University of Ottawa
Thomas Pillow, Genentech
Medha J. Tomlinson, Abbvie
Yan Chen, Genentech